SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome
SciSparc Ltd. (SPRC)
Company Research
Source: GlobeNewswire
SciSparc to conduct the trial at the Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel TEL AVIV, Israel, Aug. 23, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced the submission of an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for its phase IIb clinical trial for its proprietary SCI-110 for the treatment of Tourette Syndrome (“TS”). “SciSparc is in a unique position to address the challenges associated with current TS treatments,” said SciSparc’s Chief Executive Officer, Oz Adler. “We believe that our proprietary SCI-110, comprised of dronabinol and palmitoylethanolamide, has the potential to revolutionize the way TS i
Show less
Read more
Impact Snapshot
Event Time:
SPRC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SPRC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SPRC alerts
High impacting SciSparc Ltd. news events
Weekly update
A roundup of the hottest topics
SPRC
News
- SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico [Yahoo! Finance]Yahoo! Finance
- SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in MexicoGlobeNewswire
- SciSparc gets Nasdaq extension to regain compliance [Seeking Alpha]Seeking Alpha
- SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid RequirementGlobeNewswire
- SciSparc, Automax enters direct import market with $13M first shipment of JAC EVs [Seeking Alpha]Seeking Alpha
SPRC
Sec Filings
- 2/13/25 - Form F-4/A
- 2/4/25 - Form 6-K
- 1/21/25 - Form POS
- SPRC's page on the SEC website